Everest Medicines Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Everest Medicines Limited
The Swedish biotech’s successful launch in the US of Tarpeyo for immunoglobulin A nephropathy is progressing well and a Chinese approval is on the horizon as partner Everest’s application is accepted by regulators.
CanSino’s global-first inhaled COVID-19 vaccine is dosed into its first noses in Shanghai, while Zhejiang Haichang, Everest Medicines and Abogen make major progress with their respective mRNA vaccine programs.
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.
- Specialty Pharmaceuticals
- Large Molecule
- Other Names / Subsidiaries